Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$149.3M
20M shares
52-week range
$6.91 – $7.94
47% from low
Exchange
NYSE
FUND
Borrow rate
3.21%
Moderate
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
www.morganstanley.comNo one on the platform currently holds MSD.
No tracked institution reports a position in MSD as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-30 | $0.1500 | 2026-07-15 |
| 2026-03-31 | $0.1400 | 2026-04-15 |
| 2025-12-19 | $0.1500 | 2026-01-15 |
| 2025-09-30 | $0.1700 | 2025-10-15 |
| 2025-06-30 | $0.1900 | 2025-07-15 |
| 2025-03-31 | $0.2200 | 2025-04-15 |
| 2024-12-13 | $0.2650 | 2025-01-15 |
| 2024-09-30 | $0.2200 | 2024-10-15 |
| 2024-06-28 | $0.2200 | 2024-07-15 |
| 2024-03-27 | $0.2100 | 2024-04-15 |
No one on the platform has traded MSD yet.
| 2023-12-14 |
| $0.2000 |
| 2024-01-12 |
| 2023-09-28 | $0.2125 | 2023-10-13 |
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$BRTX DD Cash upfront Licensing agreements: 💰 Estimated based on industry benchmarks for mid-stage out-licensing of GLP-1 assets in '24-'25 Phase 2 & Phase 3. (( BEFORE being an FDA approved drug ! )) 🔑 Big Pharma's 3 Major GLP-1 Licensing Deals 12 Months. Surge in demand for obesity treatments has led "Big Pharma" 💰 paying very significant premiums for early-stage Phase 2 & next-generation candidates FDA phase 2 and phase 3 trials. 🔑 Dec 2025 YaoPharma To $PFE 💰 $150 Million $2.09 Billion Total Phase 1 oral small-molecule GLP-1.✅️ May '24Jiangsu Hengrui ToHercules 💰 $110 Million $6.00 Billion+ Portfolio of GLP-1R agonists for global markets.✅️ Nov 2024 Gilead Sciences To Merck $MSD 💰 $125 Million* $1.80 Billion+ GLP-1/GIP co-agonist for metabolic health✅️ . 👍 *Estimated based on industry benchmarks for mid-stage out-licensing of GLP-1 assets in 2024-2025. Date Licensor (Seller) Licensee (Buyer) Upfront Cash Total Deal Value Target 👍 ✅️ Bullish on LOI for $150 million dollars cash upfront from 1 of 3 Big Pharma's that Require the 3 patents. Also New knowledge in presentation at ORS meeting by $BRTX on 3-28 is key to partnership leading to Billion dollar drug after FDA approval . ✅️
View on StockTwits ↗$BRTX DD Cash upfront Licensing agreements: 💰 Estimated based on industry benchmarks for mid-stage out-licensing of GLP-1 assets in '24-'25 Phase 2 & Phase 3. before being an FDA approved drug ! 🔑 Big Pharma's 3 Major GLP-1 Licensing Deals 12 Months. Surge in demand for obesity treatments has led "Big Pharma" 💰 paying very significant premiums for early-stage Phase 2 & next-generation candidates FDA phase 2 and phase 3 trials. 🔑 Dec 2025 YaoPharma To $PFE 💰 $150 Million $2.09 Billion Total Phase 1 oral small-molecule GLP-1.✅️ May '24Jiangsu Hengrui ToHercules 💰 $110 Million $6.00 Billion+ Portfolio of GLP-1R agonists for global markets.✅️ Nov 2024 Gilead Sciences To Merck $MSD 💰 $125 Million* $1.80 Billion+ GLP-1/GIP co-agonist for metabolic health✅️ . 👍 *Estimated based on industry benchmarks for mid-stage out-licensing of GLP-1 assets in 2024-2025. Date Licensor (Seller) Licensee (Buyer) Upfront Cash Total Deal Value Target 👍
View on StockTwits ↗From 6/3/2024, looking back across 21 Month-Ends for MSD, Percentage Change of Average Monthly Price had More Positives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $MSD #MSD #MSDStock #TickerDD #MSDPrice https://www.youtube.com/watch?v=P7lpU5OPepg
View on StockTwits ↗From 6/3/2024, looking back across 21 Month-Ends for MSD, Percentage Change of Average Monthly Price had More Positives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $MSD #MSD #MSDStock #TickerDD https://www.youtube.com/watch?v=P7lpU5OPepg
View on StockTwits ↗From 2/13/2024, looking back across 22 Month-Ends for MSD, Percentage Change of Average Monthly Price had More Positives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $MSD #MSD #MSDStock #TickerDD #MSDPrice https://www.youtube.com/watch?v=NFxn_TOAArA
View on StockTwits ↗Morgan Stanley Emerging Markets Debt Fund Sees Short Interest Decrease from 75,600 shares to 61,800 shares. $MSD https://www.marketbeat.com
View on StockTwits ↗Signal alert: $MSD - Possible Runner https://stockinvest.us/l/N8KBcYYrwV
View on StockTwits ↗Signal alert: $MSD - Undervalued https://stockinvest.us/l/RPWYavYrma
View on StockTwits ↗Signal alert: $MSD - PivotPoint bottom https://stockinvest.us/l/KiCE66LZkQ
View on StockTwits ↗$MSD $EDD Certain Morgan Stanley Closed-End Funds Declare Quarterly Dividends https://www.stocktitan.net/news/MSD/certain-morgan-stanley-closed-end-funds-declare-quarterly-0xxe2zb34nmy.html #dividends
View on StockTwits ↗Morgan Stanley Emerging Markets Debt Fund, Inc. Files SEC Form N-PX $MSD https://www.marketbeat.com/stocks/NYSE/MSD/sec-filings/
View on StockTwits ↗Morgan Stanley Emerging Markets Debt Fund Sees Short Interest Decrease from 7,000 shares to 4,900 shares. $MSD https://www.marketbeat.com/s
View on StockTwits ↗Signal alert: $MSD - PivotPoint bottom https://stockinvest.us/l/M0cQg1GmvQ
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.